{"id":24956,"date":"2023-09-18T16:36:08","date_gmt":"2023-09-18T11:06:08","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=24956"},"modified":"2024-01-08T15:35:43","modified_gmt":"2024-01-08T10:05:43","slug":"huntingtons-disease-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/huntingtons-disease-treatment","title":{"rendered":"A Turning Point: INGREZZA\u2019s Impact on Huntington\u2019s Disease Treatment and the Rise of Novel Therapies"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f67d642f52a\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f67d642f52a\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/huntingtons-disease-treatment\/#Approval_of_INGREZZA_for_Huntingtons_Disease_Treatment\" >Approval of INGREZZA for Huntington\u2019s Disease Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/huntingtons-disease-treatment\/#Promising_Therapies_in_Pipeline_for_Huntingtons_Disease_Treatment\" >Promising Therapies in Pipeline for Huntington\u2019s Disease Treatment&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/huntingtons-disease-treatment\/#Unlocking_the_Potential_of_Gene_Therapy_for_Huntingtons_Disease_Treatment\" >Unlocking the Potential of Gene Therapy for Huntington&#8217;s Disease Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/huntingtons-disease-treatment\/#Expected_Roadblocks_and_Future_of_Huntingtons_Disease_Treatment\" >Expected Roadblocks and Future of Huntington\u2019s Disease Treatment<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Huntington\u2019s disease is an incurable, rare genetic, progressive neurodegenerative disorder. According to the National Organization for Rare Disorders (NORD), about <strong>30,000<\/strong> people in the United States have Huntington\u2019s disease, and another <strong>200,000<\/strong> are at risk of developing the condition.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong><em>As per DelveInsight analysis, In the year 2022, the <\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/huntingtons-disease-epidemiology-forecast\"><strong><em>total prevalent cases of Huntington\u2019s disease<\/em><\/strong><\/a><strong><em> were found to be ~81,000 in the 7MM. As per the estimates, in 2022, the total prevalent cases of Huntington\u2019s disease were 43,000 in the US. These cases are expected to grow within the study period (2019\u20132032).<\/em><\/strong><\/p>\n<\/blockquote>\n\n\n\n<p>So far, only two drugs have been approved by the FDA for Huntington\u2019s disease treatment, but they do not treat the disease, instead, they are used to treat symptoms like chorea associated with Huntington\u2019s disease. The first was <strong>tetrabenazine<\/strong>, which was approved by the US FDA in 2008 based on the <strong>TETRA study<\/strong>. This drug is sold as <strong>XENAZINE <\/strong>by <strong>Lundbeck<\/strong>. The second was <strong>AUSTDEO (deutetrabenazine; Deuterated version of tetrabenazine)<\/strong>, which was approved by the US FDA in 2017. Both medicines have been approved to treat Huntington\u2019s disease chorea. XENAZINE was the first drug ever approved in the US for the treatment of Huntington\u2019s disease symptoms. This medication was approved with a premium price tag in the US due to its Orphan Drug designation. XENAZINE has significant side effects such as somnolence, insomnia, Parkinsonism, severe depression, fatigue, anxiety, and irritability.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/infographics\/huntingtons-disease-market\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18153012\/Huntingtons-Disease-infographic-1024x194.webp\" alt=\"Huntington\u2019s Disease infographic\" class=\"wp-image-24961\" width=\"768\" height=\"146\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18153012\/Huntingtons-Disease-infographic-1024x194.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18153012\/Huntingtons-Disease-infographic-300x57.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18153012\/Huntingtons-Disease-infographic-150x28.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18153012\/Huntingtons-Disease-infographic-768x145.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18153012\/Huntingtons-Disease-infographic-1536x291.webp 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18153012\/Huntingtons-Disease-infographic-1568x297.webp 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18153012\/Huntingtons-Disease-infographic.webp 1584w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/a><\/figure>\n\n\n\n<p>According to DelveInsight\u2019s analysts, tetrabenazine has notable flaws that <strong>Teva\u2019s AUSTEDO<\/strong> could potentially address. While Austedo has been designated a new molecular entity and an orphan drug, it was approved through the 505(b) pathway with tetrabenazine as the Reference Listed Drug (RLD). In February 2023, the US FDA-approved <strong>extended-release deutetrabenazine (AUSTEDO XR)<\/strong> tablets for <a href=\"https:\/\/www.delveinsight.com\/report-store\/tardive-dyskinesia-market\">adult patients with tardive dyskinesia<\/a> and chorea associated with Huntington\u2019s disease.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-approval-of-ingrezza-for-huntington-s-disease-treatment\"><span class=\"ez-toc-section\" id=\"Approval_of_INGREZZA_for_Huntingtons_Disease_Treatment\"><\/span><strong>Approval of INGREZZA for Huntington\u2019s Disease Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Ingrezza <\/strong>from <strong>Neurocrine Biosciences<\/strong> is poised to compete with <strong>Teva\u2019s Austedo<\/strong>, following its recent FDA approval. This opens the door to a treatment area with the potential for hundreds of millions of dollars in revenue. The FDA\u2019s green light allows Ingrezza capsules to be used in the treatment of chorea associated with Huntington\u2019s disease in adults. Ingrezza initially gained approval for <a href=\"https:\/\/www.delveinsight.com\/report-store\/tardive-dyskinesia-market\" class=\"ek-link\">tardive dyskinesia treatment<\/a> in 2017. With this second approval, Ingrezza\u2019s label now closely aligns with that of Teva Pharmaceutical Industries\u2019 Austedo, which also received approval for Huntington\u2019s disease chorea in 2017.<\/p>\n\n\n\n<p>INGREZZA stands out as the sole selective vesicular monoamine transporter 2 (VMAT2) inhibitor that allows for flexible dosing based on a patient&#8217;s response and tolerance, without the need for complex titration. With INGREZZA, it\u2019s always a straightforward one-capsule, once-daily regimen. Its FDA approval is backed by extensive clinical research, including studies conducted in collaboration with the Huntington Study Group (HSG), such as the <strong>KINECT\u00ae-HD Phase III trial<\/strong> and the ongoing <strong>KINECT\u00ae-HD2 open-label extension study<\/strong>.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWe are delighted to introduce INGREZZA to individuals affected by Huntington\u2019s Disease, as well as their devoted caregivers. This groundbreaking, once-daily, single-capsule treatment has exhibited remarkable efficacy in alleviating HD chorea during clinical trials,&#8221; expressed <\/em><strong><em>Kevin C. Gorman, CEO of Neurocrine Biosciences.<\/em><\/strong><em> \u201cWe extend our heartfelt gratitude to the Huntington&#8217;s Disease community for their invaluable contributions to this significant achievement, and our dedication to providing solutions for individuals with unmet medical needs in the realm of neurological disorders remains unwavering.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>In the late-phase KINECT-HD trial, Ingrezza met its primary endpoint by demonstrating a reduction in the Unified Huntington\u2019s Disease Rating Scale total maximal chorea score compared to baseline during Weeks 10 and 12. Patients receiving Ingrezza experienced an average improvement of 3.2 points on the 28-point scale, marking a significant reduction in chorea severity when contrasted with the placebo group. Noteworthy is Ingrezza&#8217;s achievement of blockbuster status, as it generated <strong>$1.43 billion<\/strong> in sales for Neurocrine last year. In February, Neurocrine initially anticipated Ingrezza\u2019s sales to range between <strong>$1.67 billion and $1.77 billion<\/strong> in 2023. However, the company later adjusted this estimate to a range of <strong>$1.77 billion to $1.82 billion<\/strong> in August.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18153118\/FDA-Approval-Journey-of-INGREZZA-for-Tardive-Dyskinesia-and-Huntingtons-Disease-1024x381.webp\" alt=\"FDA Approval Journey of INGREZZA for Tardive Dyskinesia and Huntington\u2019s Disease\" class=\"wp-image-24962\" width=\"768\" height=\"286\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18153118\/FDA-Approval-Journey-of-INGREZZA-for-Tardive-Dyskinesia-and-Huntingtons-Disease-1024x381.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18153118\/FDA-Approval-Journey-of-INGREZZA-for-Tardive-Dyskinesia-and-Huntingtons-Disease-300x112.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18153118\/FDA-Approval-Journey-of-INGREZZA-for-Tardive-Dyskinesia-and-Huntingtons-Disease-150x56.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18153118\/FDA-Approval-Journey-of-INGREZZA-for-Tardive-Dyskinesia-and-Huntingtons-Disease-768x285.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18153118\/FDA-Approval-Journey-of-INGREZZA-for-Tardive-Dyskinesia-and-Huntingtons-Disease.webp 1485w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-promising-therapies-in-pipeline-for-huntington-s-disease-treatment-nbsp\"><span class=\"ez-toc-section\" id=\"Promising_Therapies_in_Pipeline_for_Huntingtons_Disease_Treatment\"><\/span><strong>Promising Therapies in Pipeline for Huntington\u2019s Disease Treatment&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Key player such as <strong>Prilenia Therapeutics [Pridopidine (ACR-16; Huntexil)]<\/strong> is involved in the development of Phase III <a href=\"https:\/\/www.delveinsight.com\/report-store\/huntingtons-disease-pipeline-insight\">Huntington\u2019s disease drugs<\/a>. Whereas, Phase II drugs are being developed by companies like <strong>Annexon Biosciences [ANX005], SOM Biotech [SOM3355\/Bevantolol], Vaccinex [Pepinemab (VX15\/2503)], <\/strong>and others. Apart from these, other companies are also investigating their candidates to manage Huntington\u2019s disease in the 7MM.<\/p>\n\n\n\n<p><strong>Pridopidine (formerly Huntexil)<\/strong> is <strong>Prilenia Therapeutics\u2019<\/strong> lead asset and a first-in-class selective and potent Sigma-1-receptor (S1R) agonist with neuroprotective properties. Activation of the S1R by pridopidine enhances the clearance of toxic proteins, enhances energy production, and reduces cellular stress and inflammation. Prilenia has also received the <strong>Fast Track Designation<\/strong> for Pridopidine for the treatment of Huntington\u2019s Disease. Currently, Pridopidine is being evaluated in the ongoing Phase III (NCT04556656) global clinical trial PROOF-HD (PRidopidine Outcome on Function in Huntington\u2019s disease) in collaboration with the Huntington Study Group (HSG). As per the company, the successful outcome of PROOF-HD may lead to Pridopidine\u2019s approval as a treatment for Huntington\u2019s disease.<\/p>\n\n\n\n<p><strong>Som Biotech\u2019s<\/strong> Phase II candidate <strong>SOM3355 (bevantolol)<\/strong> is another VMAT2 inhibitor being investigated for chorea associated with Huntington&#8217;s disease. According to the company, SOM3355 differs from Tetrabenazine in interaction with VMAT2 and inhibition of VMAT1, resulting in a balanced shift in monoamine signaling that alleviates motor symptoms of Huntington&#8217;s disease while maintaining mental well-being. In October 2021, SOM Biotech announced that the FDA had granted <strong>Orphan Drug Designation (ODD)<\/strong> for SOM3355 for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/huntingtons-disease-market\">treatment of chorea movements in Huntington\u2019s disease<\/a>. A Phase II (NCT03575676) trial for this drug in Huntington\u2019s disease chorea has been completed.<\/p>\n\n\n\n<p><strong>ANX005 <\/strong>is a clinical-stage investigational monoclonal antibody intended to treat patients with antibody-mediated autoimmune and complement-mediated neurodegenerative disorders. This novel therapy is formulated for IV administration and is designed to inhibit C1q and the entire classical complement pathway. A Phase II (NCT04514367) trial of this drug for Huntington\u2019s disease has been completed. In October 2021, <strong>Annexon <\/strong>was granted <strong>orphan drug designation<\/strong> for the treatment of Huntington\u2019s disease by the FDA.<\/p>\n\n\n\n<p><strong>VX15\/2503 (pepinemab)<\/strong> is a novel humanized monoclonal IgG4 antibody that binds and blocks the signaling activity of SEMA4D. SEMA4D is an extracellular signaling molecule that regulates the migration and activation of immune and inflammatory cells at sites of injury and cancer. Preclinical testing has demonstrated the beneficial effects of anti-SEMA4D treatment in a variety of neurodegenerative disease models. Vaccinex is committed to the development of this important antibody that has the potential to help people with different neurodegenerative disorders that share common mechanisms of pathology. Vaccinex has completed the Phase II (NCT02481674; SIGNAL-HD) clinical trial to evaluate the effect of pepinemab in both early manifest and late prodromal <a href=\"https:\/\/www.delveinsight.com\/report-store\/huntingtons-disease-epidemiology-forecast\">patients with Huntington\u2019s disease<\/a>. The endpoints of the study included safety and tolerability, clinical and behavioral outcomes, as well as measures of brain volume, metabolic activity, and inflammation. In August 2016, the FDA granted <strong>Fast-track Designation and Orphan drug designation<\/strong> to pepinemab for Huntington\u2019s disease treatment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-unlocking-the-potential-of-gene-therapy-for-huntington-s-disease-treatment\"><span class=\"ez-toc-section\" id=\"Unlocking_the_Potential_of_Gene_Therapy_for_Huntingtons_Disease_Treatment\"><\/span><strong>Unlocking the Potential of Gene Therapy for Huntington&#8217;s Disease Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Gene therapy for <a href=\"https:\/\/www.delveinsight.com\/report-store\/huntingtons-disease-market\">Huntington\u2019s disease treatment<\/a> is at the forefront of groundbreaking medical research. By addressing the genetic root cause of this devastating neurodegenerative disorder, gene therapy offers a glimmer of hope for patients and their families. Huntington\u2019s disease, an inherited condition with no known cure, is characterized by relentless deterioration of physical and cognitive abilities. Currently, only UniQure Biopharma is working in the Huntington\u2019s disease treatment space with its lead asset AMT-130.<\/p>\n\n\n\n<p>AMT-130 consists of an AAV5\u2014vector carrying an artificial microRNA specifically tailored to silence the huntingtin gene, leveraging the proprietary miQURE silencing technology. The therapeutic goal is to inhibit the production of the mutant protein (mHTT). Using AAV vectors to deliver microRNAs (miRNAs) directly to the brain for non-selective knockdown of the huntingtin gene represents a highly innovative and promising approach to treating Huntington\u2019s disease. The drug has received <strong>orphan drug designation and fast-track designation<\/strong> from the FDA for Huntington\u2019s disease treatment and is currently in Phase I\/II (NCT05243017, NCT04120493) study of clinical development. The drug has been granted <strong>orphan drug designation<\/strong> by the FDA and the EMA and has also been granted the <strong>fast track designation<\/strong> by the FDA for Huntington\u2019s disease treatment.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18153205\/Key-Therapies-in-Huntingtons-Disease-Pipeline-1024x505.webp\" alt=\"Key Therapies in Huntington\u2019s Disease Pipeline\" class=\"wp-image-24963\" width=\"768\" height=\"379\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18153205\/Key-Therapies-in-Huntingtons-Disease-Pipeline-1024x505.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18153205\/Key-Therapies-in-Huntingtons-Disease-Pipeline-300x148.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18153205\/Key-Therapies-in-Huntingtons-Disease-Pipeline-150x74.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18153205\/Key-Therapies-in-Huntingtons-Disease-Pipeline-768x379.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18153205\/Key-Therapies-in-Huntingtons-Disease-Pipeline.webp 1131w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-expected-roadblocks-and-future-of-huntington-s-disease-treatment\"><span class=\"ez-toc-section\" id=\"Expected_Roadblocks_and_Future_of_Huntingtons_Disease_Treatment\"><\/span><strong>Expected Roadblocks and Future of Huntington\u2019s Disease Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The lack of approved therapy for Huntington\u2019s disease treatment is not just a limitation for the patients but for the pharmaceutical giants as well. Undoubtedly, companies are trying to do their part by developing much-needed therapies, however, the high failure rate of <a href=\"https:\/\/www.delveinsight.com\/report-store\/huntingtons-disease-pipeline-insight\">emerging therapies for Huntington\u2019s disease treatment<\/a> is the major barrier. Not just one or two, but several candidates have failed so far. Both the developer and Huntington\u2019s community was optimistic about a few candidate which eventually turned out to be the opposite. The biggest blow came with the failure of late-stage candidate tominersen.<\/p>\n\n\n\n<p>Recently, <strong>Wave Life Sciences<\/strong> announced that their two antisense oligonucleotides (ASOs) in Phase I\/II studies in Huntington\u2019s disease patients did not successfully reduce mutant huntingtin levels, hence the company decided to discontinue those products. Roche\/Ionis antisense asset tominersen had the same fate. The failure of<strong> Roche and Ionis\u2019s late-stage candidate tominersen<\/strong> had already cast doubt on Wave\u2019s approach. Development and approval of a novel therapy that treat Huntington\u2019s disease is a major unmet need, and at present, a handful of companies are working toward that goal.<\/p>\n\n\n\n<p>Moreover, recent advancements in gene therapy are changing the <a href=\"https:\/\/www.delveinsight.com\/report-store\/huntingtons-disease-market\">landscape of Huntington\u2019s disease treatment<\/a>. Innovative approaches, including gene silencing, gene editing, and gene replacement, are being developed to combat the aberrant HTT gene responsible for the production of the toxic mutant huntingtin protein. These therapies aim not only to halt the progression of the disease but also to potentially reverse its devastating effects. While challenges such as efficient brain delivery, long-term efficacy, safety concerns, and ethical considerations remain, the relentless pursuit of solutions is reshaping the future of Huntington\u2019s disease treatment. Collaborative efforts between researchers, healthcare professionals, and Huntington\u2019s disease community provide the foundation for unlocking the potential of gene therapy, holding the promise of a brighter future for those affected by this challenging condition.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/huntingtons-disease-market\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18152942\/Huntingtons-Disease-Market-Outlook-1024x256.webp\" alt=\"Huntington\u2019s Disease Market Outlook\" class=\"wp-image-24960\" width=\"768\" height=\"192\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18152942\/Huntingtons-Disease-Market-Outlook-1024x256.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18152942\/Huntingtons-Disease-Market-Outlook-300x75.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18152942\/Huntingtons-Disease-Market-Outlook-150x38.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18152942\/Huntingtons-Disease-Market-Outlook-768x192.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18152942\/Huntingtons-Disease-Market-Outlook-1536x384.webp 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18152942\/Huntingtons-Disease-Market-Outlook-1568x392.webp 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18152942\/Huntingtons-Disease-Market-Outlook.webp 1584w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Huntington\u2019s disease is an incurable, rare genetic, progressive neurodegenerative disorder. According to the National Organization for Rare Disorders (NORD), about 30,000 people in the United States have Huntington\u2019s disease, and another 200,000 are at risk of developing the condition. As per DelveInsight analysis, In the year 2022, the total prevalent cases of Huntington\u2019s disease were [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":24957,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[305,12745,12744,12746,1218,2505],"industry":[17225],"therapeutic_areas":[17238],"class_list":["post-24956","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-huntingtons-disease","tag-huntingtons-disease-market","tag-huntingtons-disease-pipeline","tag-huntingtons-disease-treatment","tag-ingrezza","tag-neurocrine-biosciences","industry-pharmaceutical","therapeutic_areas-genetic-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Huntington&#039;s Disease Treatment: What Lies Ahead?<\/title>\n<meta name=\"description\" content=\"Launch of Ingrezza has opened door for Huntington&#039;s disease treatment with potential for hundreds of millions of dollars in revenue.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/huntingtons-disease-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Huntington&#039;s Disease Treatment: What Lies Ahead?\" \/>\n<meta property=\"og:description\" content=\"Launch of Ingrezza has opened door for Huntington&#039;s disease treatment with potential for hundreds of millions of dollars in revenue.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/huntingtons-disease-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-18T11:06:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-08T10:05:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18152815\/huntingtons-disease-treatment.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Huntington's Disease Treatment: What Lies Ahead?","description":"Launch of Ingrezza has opened door for Huntington's disease treatment with potential for hundreds of millions of dollars in revenue.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/huntingtons-disease-treatment","og_locale":"en_US","og_type":"article","og_title":"Huntington's Disease Treatment: What Lies Ahead?","og_description":"Launch of Ingrezza has opened door for Huntington's disease treatment with potential for hundreds of millions of dollars in revenue.","og_url":"https:\/\/www.delveinsight.com\/blog\/huntingtons-disease-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-09-18T11:06:08+00:00","article_modified_time":"2024-01-08T10:05:43+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18152815\/huntingtons-disease-treatment.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/huntingtons-disease-treatment","url":"https:\/\/www.delveinsight.com\/blog\/huntingtons-disease-treatment","name":"Huntington's Disease Treatment: What Lies Ahead?","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/huntingtons-disease-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/huntingtons-disease-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18152815\/huntingtons-disease-treatment.webp","datePublished":"2023-09-18T11:06:08+00:00","dateModified":"2024-01-08T10:05:43+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Launch of Ingrezza has opened door for Huntington's disease treatment with potential for hundreds of millions of dollars in revenue.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/huntingtons-disease-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/huntingtons-disease-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18152815\/huntingtons-disease-treatment.webp","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18152815\/huntingtons-disease-treatment.webp","width":1200,"height":800,"caption":"huntingtons-disease-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/09\/18152815\/huntingtons-disease-treatment-300x200.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Huntington\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Huntington\u2019s disease Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Huntington\u2019s disease Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Huntington\u2019s disease Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">INGREZZA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Neurocrine Biosciences<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Huntington\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">Huntington\u2019s disease Market<\/span>","<span class=\"advgb-post-tax-term\">Huntington\u2019s disease Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Huntington\u2019s disease Treatment<\/span>","<span class=\"advgb-post-tax-term\">INGREZZA<\/span>","<span class=\"advgb-post-tax-term\">Neurocrine Biosciences<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Sep 18, 2023","modified":"Updated on Jan 8, 2024"},"absolute_dates_time":{"created":"Posted on Sep 18, 2023 4:36 pm","modified":"Updated on Jan 8, 2024 3:35 pm"},"featured_img_caption":"huntingtons-disease-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/24956","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=24956"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/24956\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/24957"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=24956"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=24956"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=24956"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=24956"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=24956"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}